

FPS groups are looking for R2 researchers who can apply for competitive HR grant from the 2023 call **POSDOCTORAL JUNIOR LEADER- RETAINING Modality** of the *Fundación La Caixa*:

Application submission: from July 17th to October 5th 2023 at 2:00 PM.

Eligibility requirements:

• Research training:

 Those who obtained their doctoral degree (PhD) two to seven years prior to the application deadline are eligible. For such purposes, candidates must have obtained their doctoral degree between 5th October 2016 and 5th October 2021, both inclusive. The date of the defence for the doctoral thesis will be understood as the date the doctorate (PhD) was obtained. Should an applicant hold more than one doctorate (PhD), the above-mentioned period will be calculated for the first degree earned.

In the event of an interruption of the research activity between the date of obtaining the doctoral degree and the call deadline (5th October 2023), the period in which the doctoral degree must have been obtained may be extended beyond seven years.

• Mobility:

• Candidates **have resided** or **have carried out their main activity** (work, studies, etc.) in **Spain** for more than twelve months in the three years immediately prior to the application deadline.

Special deadlines will apply to candidates with interruptions in their research careers and to those researchers who have gone through the process to obtain refugee status under the Geneva Convention.

• International stays:

 Candidate must have carried out research stays at non-Spanish research centres or universities during their doctorate or postdoctorate, whether of a continuous or discontinuous nature for at least six months prior to the deadline for applications.

More information



Information on host group:

1. Group: Retinal Degeneration: from genetics to therapy.

Principal Investigator of the Group: <u>Francisco Javier Díaz Corrales</u>. CABIMER (Andalusian Centre of Molecular Biology and Regenerative Medicine).

Research line in which the candidate will work: The postdoctoral researcher will work on evaluating the safety and efficacy of gene therapy approaches to treat retinitis pigmentosa.

Summary of research line: Retinitis pigmentosa is the leading cause of hereditary blindness in adults. Gene therapy is opening a path of therapeutic possibilities for this disease. Our laboratory is interested in strengthening this research line by promoting preclinical studies.

Profile of the desired candidate:

• The candidate should have expertise in cellular and molecular biology and training to work with murine models of human diseases.

More information about the research group here: <u>Retinal Degeneration: from genetics to</u> therapy

Principal Investigator contact: <u>francisco.diaz@cabimer.es</u>

2. Group: Metabolism, Immunology and Cardiovascular Risk.

Principal Investigator of the Group: <u>Inés Pineda Torra</u>. CABIMER (Andalusian Centre of Molecular Biology and Regenerative Medicine).

Research line in which the candidate will work: <u>Sex differences in cardiovascular risk:</u> <u>understanding the mechanisms underlying differences in metabolism and immune responses.</u>

Summary of research line: Cardiovascular disease (CVD) has traditionally been considered to predominantly affect men, however, it is the leading cause of mortality for women worldwide. Despite this, women remain understudied. Atherosclerosis, main pathology underlying ischemic CVD, results from abnormal blood lipids and exacerbated inflammation. Lipid profiles and immune responses, key in initiating and progressing atherosclerosis, vary substantially between sexes. We will use human immune cells from age-matched groups and mice models of atherosclerosis to assess the impact of



pathways/metabolites identified through previous high-throughput analyses on the immune response.

Profile of the desired candidate:

- We are looking for a motivated, result-driven postdoctoral investigator with planning and project management skills, initiative and able to work in a team.
- Previous experience in cell culture, flow cytometry, transcriptional regulation, immunology, metabolism and/or high throughput transcriptomic analysis will be positively valued.

More information about the research group here: <u>Metabolism, Immunology and</u> <u>Cardiovascular Risk</u>

Principal Investigator contact: ines.pineda@cabimer.es

3. Group: Biomedical Magnetic Resonance Lab (BMRL).

Principal Investigator of the Group: <u>María Luisa García-Martín</u>. Biomedical Research Institute of Malaga and Nanomedicine Platform (IBIMA-BIONAND Platform).

Research line in which the candidate will work: <u>Development of theranostic magnetic</u> <u>nanosystems to tackle solid tumors.</u>

Summary of research line: This research is focused on the development of multifunctional magnetic metallic nanoparticles with capabilities as MRI probes and as therapeutic agents acting as hyperthermia mediators and/or delivery carriers, with special emphasis on tumor targeting strategies.

Profile of the desired candidate:

- Ph.D. in an area of knowledge related to the work to be developed (Health Sciences, Biological Sciences, Biotechnology, Chemical Sciences, Chemical Technology, Nanomedicine).
- Experience in the synthesis, functionalization and characterization of metallic nanoparticles.
- Experience in organic chemistry.
- Knowledge of preclinical Imaging techniques, preferably MRI.
- Fluency in English spoken and written.

More information about the research group here: <u>Biomedical Magnetic Resonance Lab</u>

Principal Investigator contact: mlgarcia@ibima.eu